Drug intelligence / Profile preview

miR-331-3p pre-miR

Development stage
Preclinical
Lead developer
University Hospital Halle (Saale)
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

miR-331-3p pre-miR is a synthetic microRNA precursor (mimic) designed to overexpress miR-331-3p, a highly conserved microRNA that plays a critical role in vascular remodeling and the progression of atherosclerosis. Research conducted at the University Hospital Halle indicates that miR-331-3p levels are significantly elevated during disease progression in atherosclerotic models, driven by pro-inflammatory cytokines such as IFNγ, IL-1β, and TNFα. The administration of miR-331-3p pre-miR in experimental settings promotes the proliferation, migration, and anti-apoptotic behavior of smooth muscle cells (SMCs), which are key processes in plaque development. It exerts these effects by modulating several downstream targets, including DUSP5 and PHLPP1. While the pre-miR is used to study the pathological effects of miR-331-3p, therapeutic strategies are focused on inhibiting this microRNA to mitigate vascular remodeling without compromising endothelial cell function.

Brand names
Pre-miR
Other names
miR-331-3p mimicmiR331-3p mimicmiR 331-3p mimichsa-miR-331-3p mimichsa-miR331-3p mimichsa-miR 331-3p mimicmicroRNA-331-3p precursormicroRNA331-3p precursormicroRNA 331-3p precursor
02

Targets

Bcl-2 homologous antagonist/killer 1 (BAK1) mRNADUSP5 (Dual specificity protein phosphatase 5)KLF16PHLPP1BAKSOCS1 (Suppressor of cytokine signaling 1)TGFBR1TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on miR-331-3p pre-miR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-331-3p pre-miR.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call